Lv31
350 积分 2024-07-06 加入
Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?
11天前
已完结
Immunotherapy-associated Autoimmune Hemolytic Anemia
20天前
已完结
Immune hemolytic anemia associated with the use of immune checkpoint inhibitors: a scoping review
21天前
已完结
Fertility and pregnancy issues in BRCA -mutated breast cancer patients
23天前
已完结
Fertility counseling for patients with hereditary breast and ovarian cancer syndrome
23天前
已关闭
Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance
28天前
已完结
STEREOTACTIC BODY RADIOTHERAPY FOR OLIGOPROGRESSIVE OVARIAN CANCER PATIENTS TREATED DURING PARP INHIBITOR MAINTENANCE: EFFICACY AND ADVERSE EVENTS FROM THE EPIMETHEO RETROSPECTIVE STUDY
28天前
已关闭
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients
28天前
已完结
STEREOTACTIC ABLATIVE RADIOTHERAPY FOR OLIGOMETASTATIC OVARIAN CANCER LYMPH NODE DISEASE: THE MITO-RT3/RAD PHASE II TRIAL
29天前
已完结
Role of salvage radiotherapy for recurrent ovarian cancer
29天前
已完结
皖公网安备34019202002308
